Development of therapeutic agents for older patients with acute myelogenous leukemia

Research output: Contribution to journalReview article

Abstract

Acute myelogenous leukemia (AML) is a disease more common in older patients than in the young. It is increasingly recognized that conventional cytotoxic chemotherapies used in children and young adults may not be appropriate in older adults because of diverse host- and disease-biology factors. This review highlights some of the most promising new treatment options that are being evaluated for older patients with AML. These options include CPX-351 (Celator Pharmaceuticals Inc), a unique liposomal formulation of a fixed ratio of cytarabine and daunorubicin; timed sequential therapy with the CDK inhibitor alvocidib (flavopiridol; sanofi-aventis/NCI); the second-generation purine nucleoside analog clofarabine; the farnesyltransferase inhibitor tipifarnib (Johnson & Johnson Pharmaceutical Research and Development LLC); and the DNA methyltransferase inhibitors decitabine and azacitidine.

Original languageEnglish (US)
Pages (from-to)669-677
Number of pages9
JournalCurrent Opinion in Investigational Drugs
Volume11
Issue number6
StatePublished - Jun 1 2010

Keywords

  • Acute myeloid leukemia
  • Chemotherapy
  • Elderly adult
  • Molecular predictor
  • Older adult
  • Poor-risk factor

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Development of therapeutic agents for older patients with acute myelogenous leukemia'. Together they form a unique fingerprint.

  • Cite this